Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

403 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of novel genetic loci for risk of multiple myeloma by functional annotation.
Macauda A, Briem K, Clay-Gilmour A, Cozen W, Försti A, Giaccherini M, Corradi C, Sainz J, Niazi Y, Ter Horst R, Li Y, Netea MG, Vogel U, Hemminki K, Slager SL, Varkonyi J, Andersen V, Iskierka-Jazdzewska E, Mártinez-Lopez J, Zaucha J, Camp NJ, Rajkumar SV, Druzd-Sitek A, Bhatti P, Chanock SJ, Kumar SK, Subocz E, Mazur G, Landi S, Machiela MJ, Jerez A, Norman AD, Hildebrandt MAT, Kadar K, Berndt SI, Ziv E, Buda G, Nagler A, Dumontet C, Raźny M, Watek M, Butrym A, Grzasko N, Dudzinski M, Rybicka-Ramos M, Matera EL, García-Sanz R, Goldschmidt H, Jamroziak K, Jurczyszyn A, Clavero E, Giles GG, Pelosini M, Zawirska D, Kruszewski M, Marques H, Haastrup E, Sánchez-Maldonado JM, Bertsch U, Rymko M, Raab MS, Brown EE, Hofmann JN, Vachon C, Campa D, Canzian F. Macauda A, et al. Among authors: dumontet c. Leukemia. 2023 Nov;37(11):2326-2329. doi: 10.1038/s41375-023-02022-8. Epub 2023 Sep 18. Leukemia. 2023. PMID: 37723249 Free PMC article. No abstract available.
Combined effects of exercise and immuno-chemotherapy treatments on tumor growth in MC38 colorectal cancer-bearing mice.
Gouez M, Rébillard A, Thomas A, Beaumel S, Matera EL, Gouraud E, Orfila L, Martin B, Pérol O, Chaveroux C, Chirico EN, Dumontet C, Fervers B, Pialoux V. Gouez M, et al. Among authors: dumontet c. Front Immunol. 2024 Feb 15;15:1368550. doi: 10.3389/fimmu.2024.1368550. eCollection 2024. Front Immunol. 2024. PMID: 38426110 Free PMC article.
A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models.
Chettab K, Fitzsimmons C, Novikov A, Denis M, Phelip C, Mathé D, Choffour PA, Beaumel S, Fourmaux E, Norca P, Kryza D, Evesque A, Jordheim LP, Perrial E, Matera EL, Caroff M, Kerzerho J, Dumontet C. Chettab K, et al. Among authors: dumontet c. Front Immunol. 2023 May 8;14:1066402. doi: 10.3389/fimmu.2023.1066402. eCollection 2023. Front Immunol. 2023. PMID: 37223101 Free PMC article.
The landscape of rare genetic variants in familial Waldenström macroglobulinemia.
Pemov A, Kim J, Luo W, Liu J, Graham C, Jones K, DeMangel D, Freedman ND, Dumontet C, Zhu B, McMaster ML, Stewart DR. Pemov A, et al. Among authors: dumontet c. Blood Neoplasia. 2024 Jun;1(2):100013. doi: 10.1016/j.bneo.2024.100013. Epub 2024 Apr 12. Blood Neoplasia. 2024. PMID: 39036705 Free PMC article.
Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma.
Eckmann J, Fauti T, Biehl M, Zabaleta A, Blanco L, Lelios I, Gottwald S, Rae R, Lechner S, Bayer C, Dekempe Q, Osl F, Carrié N, Kassem S, Lorenz S, Christopeit T, Carpy A, Bujotzek A, Bröske AE, Dekhtiarenko I, Attig J, Kunz L, Cremasco F, Adelfio R, Fertig G, Dengl S, Gassner C, Bormann F, Kirstenpfad C, Kraft TE, Diggelmann S, Knobloch M, Hage C, Feddersen R, Heidkamp G, Pöschinger T, Mayoux ML, Bernasconi L, Dumontet C, Prosper F, Martinet L, Leclair S, Xu W, Paiva B, Klein C, Umaña P. Eckmann J, et al. Among authors: dumontet c. Blood. 2024 Oct 30:blood.2024025987. doi: 10.1182/blood.2024025987. Online ahead of print. Blood. 2024. PMID: 39476124
End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy.
Sesques P, Karlin L, Massy E, Maarek A, Aussedat G, Lazareth A, Golfier C, Bouafia-Sauvy F, Lequeu H, Ghergus D, Safar V, Ferrant E, Bachy E, Ghesquières H, Confavreux CB, Demangel D, Perrial E, Dumontet C. Sesques P, et al. Among authors: dumontet c. Front Oncol. 2024 Oct 31;14:1436587. doi: 10.3389/fonc.2024.1436587. eCollection 2024. Front Oncol. 2024. PMID: 39544298 Free PMC article.
The synergy between alkylating agents and ERCC1-XPF inhibitors is p53 dependent.
Ciniero G, Pedro TM, Dumontet C, Elmenoufy AH, West FG, Weinfeld M, Gentile F, Tuszynski JA, Cros-Perrial E, Jordheim LP. Ciniero G, et al. Among authors: dumontet c. Fundam Clin Pharmacol. 2024 Nov 8. doi: 10.1111/fcp.13043. Online ahead of print. Fundam Clin Pharmacol. 2024. PMID: 39520092
Antibody-drug conjugates come of age in oncology.
Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Dumontet C, et al. Nat Rev Drug Discov. 2023 Aug;22(8):641-661. doi: 10.1038/s41573-023-00709-2. Epub 2023 Jun 12. Nat Rev Drug Discov. 2023. PMID: 37308581 Review.
403 results